Welcome to our dedicated page for Cytokinetics news (Ticker: CYTK), a resource for investors and traders seeking the latest updates and insights on Cytokinetics stock.
Cytokinetics, Incorporated develops and commercializes muscle-directed cardiovascular medicines, led by MYQORZO® (aficamten), a cardiac myosin inhibitor approved in the U.S., Europe and China for adults with symptomatic obstructive hypertrophic cardiomyopathy. Company news regularly covers MYQORZO clinical data, launch activity, regulatory approvals and analyses from HCM studies including SEQUOIA-HCM, MAPLE-HCM, FOREST-HCM and ACACIA-HCM.
Recurring updates also address Cytokinetics’ pipeline in cardiac muscle dysfunction, including omecamtiv mecarbil for heart failure with severely reduced ejection fraction and ulacamten for heart failure with preserved ejection fraction. Financial releases and corporate announcements include product revenue, operating updates, shareholder voting matters, common stock offerings and other capital-structure developments.
Cytokinetics has appointed Nancy Wysenski to its Board of Directors, strengthening its commercial and market access expertise as the company advances its drug pipeline. Wysenski brings over 25 years of experience in biopharmaceuticals, having previously held senior roles at Vertex Pharmaceuticals and Endo Pharmaceuticals. Her expertise in commercialization and organizational leadership is expected to play a crucial role as Cytokinetics navigates regulatory processes and prepares for potential marketing authorizations for its key products, including omecamtiv mecarbil and reldesemtiv.
Cytokinetics announced promising preclinical findings from studies on cardiac myosin inhibitors CK-274 and CK-271 presented at the AHA Scientific Sessions 2020. CK-274 significantly reduced left ventricular outflow tract peak pressure gradient in cats with hypertrophic cardiomyopathy (HCM), achieving a mean reduction of 13.6% to 15.4%. CK-271 showed effectiveness in mitigating fibrosis and diastolic dysfunction in an animal model of heart failure with preserved ejection fraction (HFpEF), with significant reductions in fractional shortening and diastolic parameters.
Cytokinetics (Nasdaq: CYTK) presented new analyses at the AHA Scientific Sessions 2020 highlighting the challenges in treating heart failure and hypertrophic cardiomyopathy (HCM). Key findings included significant healthcare costs for Medicare patients with heart failure, totaling approximately $16.5 billion over three years. Additionally, a study revealed high rates of hospitalization and mortality among patients with worsening heart failure events. The company is advancing CK-274, a cardiac myosin inhibitor, to improve outcomes for HCM patients, reflecting its commitment to addressing these unmet medical needs.
Cytokinetics announced positive primary results from the GALACTIC-HF trial of omecamtiv mecarbil, a Phase 3 cardiovascular outcomes study involving 8,256 patients. The trial met its primary endpoint, showing a statistically significant reduction in heart failure events or cardiovascular death compared to placebo (hazard ratio 0.92, p=0.025). However, it did not meet secondary endpoints, including a reduction in cardiovascular death. The treatment showed consistent benefits across subgroups, particularly in patients with lower ejection fraction. An investor event is scheduled for November 13, 2020.
Cytokinetics (Nasdaq: CYTK) announced on October 30, 2020, the grant of stock options to new employee Cuong Nguyen, totaling 2,850 shares. This decision was made as a material inducement for employment and approved by the Board's Compensation Committee. The options have an exercise price of $15.37 per share, equal to the stock's closing price on the grant date, and will vest over four years. Each option has a 10-year term and adheres to the terms of the company’s equity incentive plan.
Cytokinetics (NASDAQ: CYTK) will present primary results from the GALACTIC-HF trial, a Phase 3 clinical study of omecamtiv mecarbil for heart failure, at the AHA Scientific Sessions 2020 on November 13, 2020. The trial is one of the largest heart failure studies conducted to date, focusing on improving contractility to lower adverse outcomes. An investor/media event will also be held on the same day to discuss these results. The company is advancing other projects, including reldesemtiv for ALS and CK-274 for hypertrophic cardiomyopathy, while collaborating with Amgen and Astellas on various drug candidates.
Cytokinetics (CYTK) reported its Q3 2020 financial results, achieving revenues of $41.7 million, significantly up from $6.1 million in Q3 2019. The net loss narrowed to $3.2 million or $0.05 per share, improving from a $29.6 million loss in the prior year. The company announced positive topline results from the GALACTIC-HF trial, meeting its primary endpoint in reducing cardiovascular death or heart failure events, and is set to present further findings at the AHA Scientific Sessions on November 13, 2020.
Cytokinetics (CYTK) will announce its third quarter results on November 4, 2020, at 4:00 PM ET. Following the results, management will host a conference call at 4:30 PM ET to discuss financial and operational outcomes, along with future outlooks. Investors can access the call through Cytokinetics' website or by phone. A replay will be available until November 18, 2020. The company is recognized for its innovative research in muscle biology, developing drugs like omecamtiv mecarbil and reldesemtiv, aimed at treating muscle performance-related diseases.
Cytokinetics (NASDAQ:CYTK) announced that its Phase 3 trial, GALACTIC-HF, confirmed the primary composite endpoint of reducing cardiovascular death or heart failure events with omecamtiv mecarbil. The trial showed a statistically significant reduction (HR: 0.92; p=0.0252) compared to placebo, although it did not meet the secondary endpoint of reducing cardiovascular death. The large-scale trial involved 8,256 patients across 35 countries. Further data analysis is ongoing, with results to be presented at the AHA Scientific Sessions on November 13, 2020.
Cytokinetics, Inc. (Nasdaq: CYTK) announced on October 5, 2020, that it granted stock options for 10,950 shares to three new employees as an incentive for their employment, effective September 30, 2020. The options have an exercise price of $21.65 per share, equal to the stock's closing price on the grant date, and will vest over four years. This move aligns with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants. Cytokinetics focuses on developing novel muscle activators and inhibitors to treat conditions affecting muscle performance.